LHX three-lens brief
Evidence-based stock research on LHX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Analyst mean target $379.67 — 32% above current (18 analysts).
- Earnings scheduled 2026-07-24.
LHX closed at $288.32 (-0.53%) as of 2026-07-10. Market cap: $53.71B. P/E (trailing) 31.3. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $379.67 — 32% above current (18 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $5.74B, net income $512.00M. Watching for: 2026-07-24 earnings release (13 days out).
Why three lenses on LHX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine LHXacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/LHX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath LHX brief"></iframe>